Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) submitted its Monthly Return to the Hong Kong Stock Exchange for the period ended 31 May 2026, confirming that no adjustments occurred in either authorised or issued share capital during the month.

Authorised/Registered Share Capital • Ordinary H shares: 154.33 million shares at RMB 0.20 par value, representing RMB 30.87 million. • Ordinary domestic shares: 171.65 million shares at RMB 0.20 par value, representing RMB 34.33 million. Total authorised share capital remained unchanged at RMB 65.20 million.

Issued Shares • H shares outstanding: 154.33 million (no treasury shares). • Domestic shares outstanding: 171.65 million. Combined issued share count stands at 325.98 million shares, identical to the prior month.

Public Float The company affirmed compliance with the Main Board Rule 13.32D(1) requirement that at least 25% of its H-share class be held by the public.

Corporate Actions The filing notes no activity in share options, warrants, convertible securities, treasury shares, or other share-issuance arrangements during May 2026.

The report was authorised by Executive Director Liu Yanjun and submitted on 01 June 2026.